熱門資訊> 正文
展望治疗宣布任命首席执行官
2025-07-01 20:22
- Outlook Therapeutics (NASDAQ:OTLK) has named Bob Jahr as chief executive officer and a member of its board.
- Jahr succeeds interim CEO Lawrence A. Kenyon, who will continue as chief financial officer and board member.
- Jahr brings over 20 years of commercial leadership in biopharma, including roles at Sobi NA, UCB Pharma, and Amgen.
- Source: Press release
More on Outlook Therapeutics
- Outlook Therapeutics drops 17%, prices $13M stock offering
- Outlook Therapeutics gets FDA review acceptance for wet AMD treatment
- Seeking Alpha’s Quant Rating on Outlook Therapeutics
- Historical earnings data for Outlook Therapeutics
- Financial information for Outlook Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
